REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients

Clinical Trial

NCT04276558 Recruiting, Active

Efficacy, Safety and Pharmacokinetics of 3 Doses of REC 0/0559 Eye Drops for the Treatment of Stage 2 (Moderate) and 3 (Severe) Neurotrophic Keratitis in Adult Patients

Phase 2

Interventional

Disease

Disease type

Other

Patient type

Adult

Children

Inclusion / Exclusion

Opening date

13/10/2020

Closing date

30/04/2024

Inclusion criteria :

Exclusion criteria :

Funding

private

Members involved

Others investigators

Dr Claudia Priglinger

Representative

Germany

Dr Yannick Lemer

Representative

France

Pr Dominique BREMOND-GIGNAC

Representative

France

Anterior Segment Rare Eye Diseases (WG4), CPMS & Digital Medecine (TWG10), Genetic Diagnostics (TWG6), Low Vision Daily Life and Patients Groups (TWG5), National Integration (TWG9), Neuro-Ophthalmology Rare Diseases (WG2), Pediatric Ophthalmology Rare Diseases (WG3), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)

Working Group Leader

Pr Philipp Albrecht

Representative

Germany

Dr Giacomo Maria Bacci

Representative

Italy

Anterior Segment Rare Eye Diseases (WG4), Genetic Diagnostics (TWG6), Low Vision Daily Life and Patients Groups (TWG5), Pediatric Ophthalmology Rare Diseases (WG3), Retinal Rare Eye Diseases (WG1)

Dr JAIME ETXEBARRIA

Representative

Spain

Anterior Segment Rare Eye Diseases (WG4)

Pr Julian Garcia Feijoo

Representative

Spain

CPMS & Digital Medecine (TWG10), Genetic Diagnostics (TWG6), Low Vision Daily Life and Patients Groups (TWG5), National Integration (TWG9), Pediatric Ophthalmology Rare Diseases (WG3), Research (TWG8)